| Objective To study the change of platelet activity marker GMP-140 and fibrinolytic activity in combined hyperlipidemic patients; to investigate the effects of Lipid-lowering therapy with Xuezhikang on GMP-140 concentration and fibrinolytic activity. Methods Thirty combined hyperlipidemic patients and twenty healthy volunteers participated in the study. Serum Lipid leveK GMP-140 concentration ^ t-PA activity and PAI activity were measured in all subjects. Then hyperlipidemic patients were treated with Xuezhikang (0.6 twice daily) for 8 weeks. At the end of 8 weeks treatment with Xuezhikang, serum Lipid leveK GMP-140 concentration t-PA activity and PAI activity were remeasured. Results Compared with normal control group, hyperlipidemic patients showed a significant increase in serum triglyceride and cholesterole concentration, HDL was reduced significantly (all p< 0.01); the GMP-140 concentration and PAI-1 activity were markedly elevated(all p<0.01), while t-PA activity was reduced (p <0.01)in hyperlipidemic patients. After 8 weeks treatment with Xuezhikang, There was a expected therapeutic effect on serum Lipid concentration: triglyceride and cholesterol concentration ( total cholesterol and LDL-C) was reduced (all p<0.01), while HDL-C was elevated ( p<0.05), GMP-140 concentration was reduced (p<0.01), while t-PA activity and PAI-1 activity were notimproved. PAI activity was positive related to serum triglyceride concentration.Conclusions Combined hyperlipidemic patients showedelevated platelet activity (indicated by increased GMP-140 concentration) and hypofibrinolytic activity (indicated by elevated PAI-1 activity and reduced t-PA activity). Xuezhikang can reduce serum Lipid, inhibit platelet acitivity, reduce GMP-140 concentration, but there was no significant improvement of fibrinolytic acitivity in combined hyperlipidemic patients treated with Xuezhikang for 8 weeks.Caishuxia (Cardiovascular Medicine) Directed by-Wojinshan... |
PDF Full Text Request